Share price movements
On January 30, AC Immune SA (ACIU) issued a press release announcing the discontinuation of Phase 3 trials, CREAD 1 and CREAD 2, by Roche Holdings (RHHBY). The decision was based on an interim analysis by an independent data monitoring committee. In CREAD 1 and CREAD 2, crenezumab, an investigational therapy, was being evaluated in Alzheimer’s disease indication.
The news disappointed investors and pushed down AC Immune SA’s share price to $3.65, which is 65.98% lower than its previous closing price. AC Immune SA closed at a discount of 49.02% compared to its 52-week low price of $7.16. The company closed at a discount of 79.02% compared to its 52-week high price of $17.40.
Based on AC Immune SA’s closing price on January 30, the company reported returns of -64.39% in the last week, -62.68% in the last month, and -57.21% in the last quarter. AC Immune SA also reported returns of -61.29% in the last half year, -73.16% in the last year, and -61.38% YTD.
AC Immune SA’s current market capitalization is $229.37 million. Micro-cap stocks can be riskier investments for retail investors compared to the broader market or large-cap stocks.
Analysts’ recommendations and target price
On January 31, analysts’ 12-month consensus recommendation for AC Immune SA is a “strong buy.” AC Immune SA’s 12-month consensus target price is $17.5, which is 379.45% higher than its closing price on January 30. The company’s highest, median, and lowest target price is $18, $18, and $16, respectively
Among the four analysts covering AC Immune SA on January 31, two recommended a “strong buy” and two recommended a “buy.”